{"id":"W2752175334","doi":"10.1007/s12282-017-0798-4","title":"Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study","year":2017,"lang":"en","type":"article","venue":"Breast Cancer","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Eisai Canada; Japan Society of Clinical Oncology","keywords":"Capecitabine; Eribulin; Medicine; Metastatic breast cancer; Dosing; Internal medicine; Pharmacokinetics; Breast cancer; Neutropenia; Taxane; Anthracycline; Oncology; Gastroenterology; Toxicity; Pharmacology; Cancer; Urology; Colorectal cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001312557,0.001974497,0.002650677,0.0007260335,0.0004777774,0.0008713279,0.001252386,0.001599084,0.003224087],"category_scores_gemma":[0.0007985972,0.0007004988,0.0008787786,0.0005223888,0.0009012591,0.0005138705,0.000312415,0.003118545,0.0008540127],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001151272,"about_ca_system_score_gemma":0.001895774,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001284521,"about_ca_topic_score_gemma":0.003712837,"domain_scores_codex":[0.9996237,0.0001524664,0.00001530006,0.00006302707,0.00005338957,0.00009219683],"domain_scores_gemma":[0.9994492,0.00006958042,0.00009857347,0.0000393542,0.00003798675,0.0003052803],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4742367,0.148864,0.01309832,0.002005713,0.001557999,0.001472602,0.0006574276,0.005219315,0.1659266,0.0009409584,0.01255798,0.1734624],"study_design_scores_gemma":[0.5810549,0.391989,0.01139016,0.00007472981,0.0003527542,0.0006856103,0.00004704161,0.001015151,0.00665406,0.0001908309,0.006507675,0.00003800293],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889843,0.003307951,0.0005369488,0.0006293693,0.000102632,0.003565845,0.0008388938,0.000109075,0.001924878],"genre_scores_gemma":[0.977094,0.004626512,0.003294094,0.002132153,0.0001996692,0.004538279,0.002708374,0.00005913287,0.005347753],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003224087,"threshold_uncertainty_score":0.01078558,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07959678551480229,"score_gpt":0.4405309141356356,"score_spread":0.3609341286208333,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}